{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:02:46Z","timestamp":1790622166115,"version":"4.1.0"},"reference-count":65,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Veterans Affairs Lung Precision Oncology Program","award":["1I50CU000157"],"award-info":[{"award-number":["1I50CU000157"]}]},{"name":"Department of Veterans Affairs Merit Review Research Grant","award":["1I01BX004717"],"award-info":[{"award-number":["1I01BX004717"]}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation of the American Society of Clinical Oncology","doi-asserted-by":"crossref","award":["20251187"],"award-info":[{"award-number":["20251187"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LUNGevity Foundation Veterans Affairs Research Scholar Award","award":["2025-07"],"award-info":[{"award-number":["2025-07"]}]},{"name":"The UCLA Isabel and Harvey Kibel Fellowship","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"USHHS Ruth L. Kirschstein Institutional National Research Service Award","award":["T32-CA009120"],"award-info":[{"award-number":["T32-CA009120"]}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T33DT6443"],"award-info":[{"award-number":["T33DT6443"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["P30 AI28697"],"award-info":[{"award-number":["P30 AI28697"]}]},{"name":"NIH","award":["P30 CA16042"],"award-info":[{"award-number":["P30 CA16042"]}]},{"name":"Lung Cancer Foundation of America and International Lung Cancer Foundation Young Investigator Award","award":["1157"],"award-info":[{"award-number":["1157"]}]},{"name":"Department of Veterans Affairs Career Development Award-2","award":["1IK2BX006194"],"award-info":[{"award-number":["1IK2BX006194"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Non-small cell lung cancer (NSCLC) frequently evades immune surveillance through defective antigen presentation and a suppressive tumor microenvironment (TME), limiting the efficacy of immune checkpoint blockade (ICB). Conventional type 1 dendritic cells (cDC1s) are essential for initiating antitumor CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses; however, their abundance and function are often diminished in NSCLC, contributing to poor outcomes and resistance to immunotherapy. We hypothesized that in situ vaccination (ISV) using gene-modified cDC1s engineered to secrete FMS-like tyrosine kinase 3 ligand (FLT3L) would enhance cDC1 function within the TME, promote antitumor immunity, and improve responses to ICB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Syngeneic murine models of NSCLC (\n                      <jats:italic>\n                        Kras\n                        <jats:sup>G12D<\/jats:sup>\n                        \/P53\n                        <jats:sup>-\/-<\/jats:sup>\n                        \/Lkb1\n                        <jats:sup>\u2212\/\u2212<\/jats:sup>\n                        ; Kras\n                        <jats:sup>G12D<\/jats:sup>\n                        \/P53\n                        <jats:sup>-\/-<\/jats:sup>\n                      <\/jats:italic>\n                      ; and\n                      <jats:italic>\n                        Kras\n                        <jats:sup>G12D<\/jats:sup>\n                      <\/jats:italic>\n                      ) with varying tumor mutational burden, along with the MC38 model, were used to assess the therapeutic efficacy of FLT3L-cDC1 ISV. Flow cytometry and multiplex immunofluorescence were used to evaluate immune mechanisms of response. To assess translational relevance, immune and tertiary lymphoid structure (TLS) signatures were analyzed in The Cancer Genome Atlas (TCGA) NSCLC datasets, with TLS signatures refined using a retrained xCell2 framework incorporating curated TLS and high endothelial venule (HEV) microdissection datasets.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      FLT3L-cDC1 ISV remodeled the TME across multiple NSCLC models, inducing T lymphocyte infiltration and expanding cytolytic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. FLT3L-cDC1 ISV was associated with increased formation of immature TLS with primary follicle-like features within the TME. TCGA analyses revealed that FLT3L expression correlates with activated DC, T cell, and B cell signatures, as well as HEV-enriched TLS-associated programs. Combination with PD-1 blockade further enhanced the antitumor immunity of FLT3L-cDC1 ISV, resulting in robust local and systemic T-cell activation and the expansion of activated CCR7\n                      <jats:sup>+<\/jats:sup>\n                      PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      cDC1s and stem-like TCF1\n                      <jats:sup>+<\/jats:sup>\n                      PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      progenitors within the TME. In an LKB1-deficient NSCLC model, FLT3L-cDC1 ISV plus PD-1 blockade induced complete and durable regression in 85% of tumors, leading to long-lasting systemic tumor-specific immune memory, consistent with effective tumor vaccination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FLT3L-cDC1 ISV represents a rational cytokine-enhanced cellular immunotherapy designed to overcome immunosuppression and restore DC function within the TME, thereby promoting tumor-specific adaptive immune responses and enhancing responsiveness to ICB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-014914","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:25:18Z","timestamp":1782397518000},"page":"e014914","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7529-1004","authenticated-orcid":false,"given":"Jensen","family":"Abascal","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Molecular Biology Institute, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Dumitras","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh M","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, California, USA"},{"name":"David Geffen School of Medicine at UCLA, UCLA Health Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Crosson","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-0190","authenticated-orcid":false,"given":"Bitta","family":"Kahangi","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Molecular Biology Institute, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0059-5677","authenticated-orcid":false,"given":"Austin","family":"Rennels","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond J","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Reyimjan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalani J","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Molecular Biology Institute, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Perez-Reyes","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Molecular Biology Institute, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostyantyn","family":"Krysan","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"David Geffen School of Medicine at UCLA, UCLA Health Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Dubinett","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"Molecular Biology Institute, UCLA, Los Angeles, California, USA"},{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, California, USA"},{"name":"David Geffen School of Medicine at UCLA, UCLA Health Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA"},{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-8062","authenticated-orcid":false,"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"David Geffen School of Medicine at UCLA, UCLA Health Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1543-5421","authenticated-orcid":false,"given":"Ramin","family":"Salehi-Rad","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"},{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, California, USA"},{"name":"David Geffen School of Medicine at UCLA, UCLA Health Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026090205002529000_14.6.e014914.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026090205002529000_14.6.e014914.2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccm.2019.10.003","article-title":"The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment","volume":"41","author":"Salehi-Rad","year":"2020","journal-title":"Clin Chest Med"},{"key":"2026090205002529000_14.6.e014914.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2026090205002529000_14.6.e014914.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026090205002529000_14.6.e014914.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2026090205002529000_14.6.e014914.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2026090205002529000_14.6.e014914.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2026090205002529000_14.6.e014914.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2026090205002529000_14.6.e014914.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"2026090205002529000_14.6.e014914.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05032-8","article-title":"A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers","volume":"9","author":"Gettinger","year":"2018","journal-title":"Nat Commun"},{"key":"2026090205002529000_14.6.e014914.11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2026090205002529000_14.6.e014914.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.002"},{"key":"2026090205002529000_14.6.e014914.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.001"},{"key":"2026090205002529000_14.6.e014914.14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s43018-020-00140-1","article-title":"Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44","volume":"1","author":"Cummings","year":"2020","journal-title":"Nat Cancer"},{"key":"2026090205002529000_14.6.e014914.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0586"},{"key":"2026090205002529000_14.6.e014914.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.007"},{"key":"2026090205002529000_14.6.e014914.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3564"},{"key":"2026090205002529000_14.6.e014914.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.04.014"},{"key":"2026090205002529000_14.6.e014914.19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1285"},{"key":"2026090205002529000_14.6.e014914.20","doi-asserted-by":"publisher","DOI":"10.1038\/S41577-019-0210-Z"},{"key":"2026090205002529000_14.6.e014914.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0473"},{"key":"2026090205002529000_14.6.e014914.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00820-z"},{"key":"2026090205002529000_14.6.e014914.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2821"},{"key":"2026090205002529000_14.6.e014914.24","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-6-38","article-title":"Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer","volume":"6","author":"Baratelli","year":"2008","journal-title":"J Transl Med"},{"key":"2026090205002529000_14.6.e014914.25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-24-0435","article-title":"Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer","volume":"24","author":"Oh","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026090205002529000_14.6.e014914.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003"},{"key":"2026090205002529000_14.6.e014914.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5030"},{"key":"2026090205002529000_14.6.e014914.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"2026090205002529000_14.6.e014914.29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070176"},{"key":"2026090205002529000_14.6.e014914.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2026090205002529000_14.6.e014914.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012"},{"key":"2026090205002529000_14.6.e014914.32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2026090205002529000_14.6.e014914.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0284"},{"key":"2026090205002529000_14.6.e014914.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8"},{"key":"2026090205002529000_14.6.e014914.35","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1615"},{"key":"2026090205002529000_14.6.e014914.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19192-z","article-title":"Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s","volume":"11","author":"Oba","year":"2020","journal-title":"Nat Commun"},{"key":"2026090205002529000_14.6.e014914.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x"},{"key":"2026090205002529000_14.6.e014914.38","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.2000.18.23.3883","article-title":"Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer","volume":"18","author":"Morse","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026090205002529000_14.6.e014914.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-545772"},{"key":"2026090205002529000_14.6.e014914.40","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00262-020-02837-9","article-title":"Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden","volume":"70","author":"Salehi-Rad","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026090205002529000_14.6.e014914.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"2026090205002529000_14.6.e014914.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-14220-x","article-title":"FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Cancer"},{"key":"2026090205002529000_14.6.e014914.43","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/s41598-025-86185-7","article-title":"FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers","volume":"15","author":"Tang","year":"2025","journal-title":"Sci Rep"},{"key":"2026090205002529000_14.6.e014914.44","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101479","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026090205002529000_14.6.e014914.45","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"2026090205002529000_14.6.e014914.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00728-0"},{"key":"2026090205002529000_14.6.e014914.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.002"},{"key":"2026090205002529000_14.6.e014914.48","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2326-6066.CIR-21-0369","article-title":"Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival","volume":"10","author":"Sawada","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026090205002529000_14.6.e014914.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.07.006"},{"key":"2026090205002529000_14.6.e014914.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.002"},{"key":"2026090205002529000_14.6.e014914.51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1439"},{"key":"2026090205002529000_14.6.e014914.52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1236"},{"key":"2026090205002529000_14.6.e014914.53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099"},{"key":"2026090205002529000_14.6.e014914.54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS ONE"},{"key":"2026090205002529000_14.6.e014914.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2026090205002529000_14.6.e014914.56","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"2026090205002529000_14.6.e014914.57","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp3978","article-title":"Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer","volume":"10","author":"Hogg","year":"2025","journal-title":"Sci Immunol"},{"key":"2026090205002529000_14.6.e014914.58","doi-asserted-by":"publisher","DOI":"10.1038\/nature10540"},{"key":"2026090205002529000_14.6.e014914.59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090205002529000_14.6.e014914.60","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0865"},{"key":"2026090205002529000_14.6.e014914.61","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat Cancer"},{"key":"2026090205002529000_14.6.e014914.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0676-7"},{"key":"2026090205002529000_14.6.e014914.63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1085547","article-title":"IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma","volume":"14","author":"Swan","year":"2023","journal-title":"Front Immunol"},{"key":"2026090205002529000_14.6.e014914.64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006896","article-title":"CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity","volume":"11","author":"Salehi-Rad","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090205002529000_14.6.e014914.65","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-025-03784-3","article-title":"xCell 2.0: robust algorithm for cell type proportion estimation predicts response to immune checkpoint blockade","volume":"26","author":"Angel","year":"2025","journal-title":"Genome Biol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:00:47Z","timestamp":1788350447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2026-014914"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014914","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}